Cemdisiran
- Generic Name
- Cemdisiran
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1639264-46-2
- Unique Ingredient Identifier
- S66Z65E10T
- Background
Cemdisiran is under investigation in clinical trial NCT03841448 (A Study of Cemdisiran in Adults With Immunoglobulin a Nephropathy (Igan)).
- Associated Conditions
- -
- Associated Therapies
- -
Eculizumab to Cemdisiran Switch in aHUS
Phase 2
Withdrawn
- Conditions
- Interventions
- Locations
- 🇮🇹
Centro di Ricerche Cliniche per le Malattie Rare " Aldo e Cele Daccò", Ranica, BG, Italy
A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT03841448
- Locations
- 🇬🇧
Clinical Trial Site, Leicester, United Kingdom
A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome
- First Posted Date
- 2017-10-06
- Last Posted Date
- 2018-10-01
- Lead Sponsor
- Alnylam Pharmaceuticals
- Registration Number
- NCT03303313
- Locations
- 🇸🇪
Clinical Trial Site, Örebro, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath